Get notified when SLN files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Emphasis of Matter (new) — The auditor's report flags a going-concern-style risk: the company needs more financing to continue its R&D.
Silence Therapeutics files 424B5 for ADS offering; terms not yet set, proceeds to fund clinical development into 2029
Filed August 10, 2026 · ~2 min read
Key Changes
-
high
Silence Therapeutics is offering ADSs, each representing three ordinary shares, with a 30-day underwriter option for additional ADSs. The number of ADSs and offering price are left blank in this preliminary prospectus supplement.
The Offering verify on EDGAR → -
high
Net proceeds are estimated but blank; funds will support clinical development and general corporate purposes, with runway into 2029 but not enough to complete development of any product candidate.
Use of Proceeds verify on EDGAR → -
high
Net tangible book value was $0.59 per ADS as of June 30, 2026, based on 47,246,393 ADSs outstanding. Investors will experience immediate and substantial dilution.
Dilution verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (GIS 10-Q) is open in full — no account needed.
Partner
Trade SLN commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 1, 2026 · How we verify